Zaniducla
(Zanidatamab)Phase 3Monoclonal antibody
Jazz PharmaceuticalsZanidatamab is used to treat certain types of stomach cancer and gastroesophageal junction cancer in patients whose tumors have specific genetic characteristics (HER2 positivity). It works by targeting and blocking cancer cells that have too much of a protein called HER2.[1] Zaniducla is currently being investigated across 12 indications[3], with its most advanced program in Phase 3.[1]
Zaniducla is one of 209 biologic programs targeting Esophageal Cancer. It is currently in Phase 3.
12
Indications
22
Total Trials
19
Active Trials
208
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 12 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Zaniducla
Jazz PharmaceuticalsPhase 3
Halaven
EisaiPreclinical
Lexiscan
AstellasPreclinical
Adenocard
AstellasPreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Aquasol E
NNational Eye Institute (NEI)
Preclinical
Zoladex
Luye Pharma Group Ltd.Preclinical
Apatinib Mesylate
BBukwang Pharmaceutical
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer4 trials
Biliary Tract Cancer2 trials
Esophageal Adenocarcinoma2 trials
HER2 Positive2 trials
11 more indications
Colon and Rectal Cancer1 trial
Patients With Solid Tumors1 trial
Advanced Malignancies1 trial
Metastatic Breast Cancer1 trial
Gastric Cancer1 trial
HER2-positive Breast Cancer1 trial
Cancers1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Zanidatamab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Receptor Protein-Tyrosine Kinase Erbb-2 Inhibitor[2]
- Modality
- Monoclonal antibody[2]
- Highest Phase
- Phase 3[1]
- Company